Physician
Heartland Pathology Consultants, PSC
Heartland Pathology Consultants, PSC was paid $2.32M by Medicaid between Jan 2018 and Nov 2024, across 113 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 28% of everything it billed.
33Billing provider infoHEARTLAND PATHOLOGY CONSULTANTS, PSC
ELIZABETHTOWN, KY 42701
ELIZABETHTOWN, KY 42701
33aNPI1730287574assigned 09/20/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$2.32M
24GClaims219,182
24DCodes billed113
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Kentucky
Rank by total paid#4 of 27
Median peer was paid$139K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 105,812 | $1.48M | |
| 2019 | 30,067 | $147K | |
| 2020 | 23,261 | $191K | |
| 2021 | 44,549 | $135K | |
| 2022 | 6,254 | $121K | |
| 2023 | 6,383 | $142K | |
| 2024incomplete | 2,856 | $98K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 28% | 15,914 | 14,444 | $657K |
| 80053 | Comprehensive metabolic panel | 11% | 26,950 | 20,509 | $248K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.7% | 31,798 | 22,146 | $179K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.7% | 7,853 | 7,470 | $110K |
| 80061 | Lipid panel | 2.7% | 5,994 | 5,821 | $63K |
| 87800 | 2.7% | 1,701 | 1,630 | $63K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.3% | 1,503 | 1,444 | $53K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.3% | 1,502 | 1,444 | $53K |
| 84702 | 2.2% | 4,276 | 3,741 | $50K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.0% | 7,128 | 6,483 | $47K |
| 88307 | 2.0% | 868 | 785 | $47K | |
| 84439 | 2.0% | 5,906 | 5,610 | $46K |
101 more codes
| 83880 | 1.6% | 1,667 | $37K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 3,580 | $36K |
| 83690 | 1.4% | 6,041 | $33K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 5,495 | $33K |
| 87070 | 1.4% | 5,837 | $33K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.3% | 3,643 | $30K |
| 88304 | 1.2% | 3,289 | $27K | |
| 83735 | 1.1% | 5,554 | $25K | |
| 82607 | 1.1% | 1,924 | $24K | |
| 87186 | 1.0% | 2,753 | $23K | |
| 87071 | <1% | 2,711 | $22K | |
| 87077 | <1% | 3,191 | $22K | |
| 84466 | <1% | 1,849 | $19K | |
| 82746 | <1% | 1,504 | $19K | |
| 87040 | <1% | 1,384 | $18K | |
| 81001 | <1% | 7,216 | $17K | |
| 85610 | <1% | 5,035 | $16K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,252 | $13K |
| 87807 | <1% | 1,326 | $13K | |
| 85730 | <1% | 2,615 | $13K | |
| 86850 | <1% | 1,274 | $13K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,928 | $12K |
| 83605 | <1% | 1,583 | $12K | |
| 87493 | <1% | 319 | $12K | |
| 80050 | General health panel | <1% | 750 | $11K |
| 88342 | <1% | 542 | $11K | |
| 83540 | <1% | 1,913 | $10K | |
| 82728 | <1% | 1,027 | $10K | |
| 82550 | <1% | 1,709 | $9K | |
| 88108 | <1% | 470 | $7K | |
| 81003 | <1% | 4,201 | $7K | |
| 84703 | <1% | 685 | $7K | |
| 84484 | <1% | 967 | $7K | |
| 82570 | <1% | 1,158 | $6K | |
| 86701 | <1% | 668 | $5K | |
| 84153 | <1% | 318 | $5K | |
| 85379 | <1% | 638 | $5K | |
| 80202 | <1% | 512 | $5K | |
| 87449 | <1% | 448 | $5K | |
| 86901 | <1% | 1,822 | $5K | |
| 82274 | <1% | 286 | $4K | |
| 84112 | <1% | 247 | $4K | |
| 84100 | <1% | 1,360 | $4K | |
| 86677 | <1% | 326 | $4K | |
| 86403 | <1% | 367 | $4K | |
| 86900 | <1% | 1,400 | $4K | |
| 82150 | <1% | 510 | $3K | |
| 86618 | <1% | 123 | $3K | |
| 80076 | <1% | 468 | $3K | |
| 85652 | <1% | 1,196 | $3K | |
| 82565 | <1% | 497 | $2K | |
| 86140 | <1% | 729 | $2K | |
| 86780 | <1% | 266 | $2K | |
| 84550 | <1% | 443 | $2K | |
| 85027 | <1% | 453 | $2K | |
| 86431 | <1% | 313 | $2K | |
| 84145 | <1% | 214 | $2K | |
| 80069 | <1% | 312 | $1K | |
| 82140 | <1% | 103 | $1K | |
| 84156 | <1% | 324 | $1K | |
| 88341 | <1% | 31 | $965.67 | |
| 83721 | <1% | 76 | $912.34 | |
| 86060 | <1% | 176 | $904.71 | |
| 83615 | <1% | 162 | $844.43 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 263 | $825.00 |
| 83970 | <1% | 13 | $742.50 | |
| 87205 | <1% | 141 | $706.49 | |
| 81025 | <1% | 615 | $664.32 | |
| 85060 | <1% | 62 | $648.68 | |
| 85046 | <1% | 86 | $508.41 | |
| 83986 | <1% | 110 | $425.04 | |
| 83001 | <1% | 44 | $398.32 | |
| 84436 | <1% | 40 | $360.02 | |
| 82947 | <1% | 94 | $344.76 | |
| 82378 | <1% | 12 | $336.21 | |
| 82962 | <1% | 1,514 | $288.64 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 14 | $258.68 |
| 89051 | <1% | 59 | $249.26 | |
| 86038 | <1% | 14 | $229.14 | |
| 82948 | <1% | 206 | $191.52 | |
| 87102 | <1% | 13 | $166.20 | |
| 82553 | <1% | 37 | $163.31 | |
| 88302 | <1% | 24 | $153.90 | |
| 88300 | <1% | 37 | $107.18 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 88 | $106.38 |
| 87278 | <1% | 44 | $81.29 | |
| 87641 | <1% | 12 | $81.00 | |
| 84146 | <1% | 13 | $55.87 | |
| 82009 | <1% | 95 | $23.60 | |
| 87660 | <1% | 209 | $20.05 | |
| 87510 | <1% | 209 | $20.05 | |
| 87480 | <1% | 209 | $20.05 | |
| 80143 | <1% | 246 | $14.91 | |
| 80179 | <1% | 238 | $14.91 | |
| 82077 | <1% | 382 | $13.82 | |
| 85007 | <1% | 169 | $7.60 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 164 | $0.00 |
| 86225 | 0% | 52 | $0.00 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | 0% | 43 | $0.00 |
| 83002 | 0% | 25 | $0.00 | |
| 87505 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGODFREY, GWENDOLYN (PRESIDENT)